ClinicalTrials.gov
public full text
Public Domain
Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of AC0010 in Advanced Non Small Cell Lung Cancer
AC0010 Maleate Capsules is a new, irreversible, Epidermal Growth Factor Receptor (EGFR) mutation selective Tyrosine Kinase Inhibitor.Aim at local advanced or metastatic non-small cell lung cancer patients with EGFR mutation or T790M drug-resistant mutation. The molecular mechanism: by irreversible combining the EGFR-RTKs ATP binding site of cell, selectively suppress the activities of EGFR tyrosine kinase phosphorylation, block the sigal signal transduction system of EGFR, and close the function of ras/raf/MAPK downstream. at last block the tumor cell growth by EGFR induction, and promotes apoptosis. AC0010 Maleate Capsules has three characters: 1. Irreversible combination with EGFR; 2.Efficient suppress the EGFR mutant tumor cell and has no suppression to EGFR wild-type cell; 3. Efficient suppress the EGFR T790M drug-resistant mutation tumor cell.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- UFUR (Tegafur/Uracil) Plus Iressa in Non-small-cell Lung Cancer#864701
- Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer#862317
- A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer#1137535
- Image 2_Case Report: Short-term response to mesenchymal epithelial transition inhibitor/epidermal growth factor receptor tyrosine kinase inhibitor combination in EGFR-mutated non-small cell lung cancer with acquired MET overexpression after progression and discussion on comprehensive management.tif#367124
- Image 1_Case Report: Short-term response to mesenchymal epithelial transition inhibitor/epidermal growth factor receptor tyrosine kinase inhibitor combination in EGFR-mutated non-small cell lung cancer with acquired MET overexpression after progression and discussion on comprehensive management.tif#367123
Record · ID 857503
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive